Keyword: Boehringer Ingelheim
The agreement tasks Adimab with turning its yeast-based antibody discovery platform against multiple targets picked out by Boehringer.
The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.
Boehringer Ingelheim is deepening its venture fund pockets from €100 million to €250 million as it looks to change up its investment strategy.
Centrexion will use the cash to move nonopioid pain drug CNTX-4975 into a phase 3 trial in patients with knee osteoarthritis in the coming months.
Germany’s Boehringer Ingelheim has entered into a deal with Evox Therapeutics, its second with a U.K.-based biotech in as many days.
Boehringer is paying €25 million upfront and committing to up to €600 million more to land an option on Autifony’s schizophrenia drug.
The big biotech participated in the round to equip Hookipa to advance its cytomegalovirus vaccine and cancer candidate through early clinical testing.
HitGen has formed a drug discovery research collaboration with Boehringer Ingelheim to identify novel small-molecule leads.
The move represents a big win for Propeller Health, which has a chance to provide its sensor-enabled inhaler and app to a large group of patients.
The pact sees Boehringer commit to up to €307 million to work with MiNA on up to three targets relevant to NASH and other fibrotic liver diseases.